Arranon Related Published Studies
Well-designed clinical trials possibly related to Arranon (Nelarabine)
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). [2009.12.10]
Other research related to Arranon (Nelarabine)
In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia. [2011.08.25]
[Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL]. [2011.06]
Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. [2010.08]
A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells. [2010.02]
Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. [2009.10]
[Severe liver injury following nelarabine chemotherapy for T-cell lymphoblastic lymphoma] [2009.01]
FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. [2008.06]
Phase I trial of nelarabine in indolent leukemias. [2008.03.01]
Nelarabine. [2008]
Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine. [2007.12]
Nelarabine: a novel purine antimetabolite antineoplastic agent. [2007.09]
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. [2007.06.15]
Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. [2006.09.15]
Nelarabine in the treatment of refractory T-cell malignant diseases. [2006.09]
Nelarabine: efficacy in the treatment of clinical malignancies. [2006.08]
Nelarabine use in leukemias. [2006.07]
Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias. [2005.06]
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. [2005.05.20]
Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. [2001.04.15]
Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. [2000.03]
Other possibly related research studies
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. [2007.01]
New drugs 07, part I. [2007.02]
Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. [2006.12]
Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. [2005.05.20]
New nucleoside analogs in the treatment of hematological disorders. [2004.05]
Nucleoside analogues in the treatment of haematological malignancies. [2001.06]
Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. [2000.12]
Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. [1999.01.01]
Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. [1998.11]
Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. [2006]
Gateways to clinical trials. [2006.06]
Pharmacological and clinical studies on purine nucleoside analogs--new anticancer agents. [2006.05]
Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. [2005.09]
Purine nucleoside antimetabolites in development for the treatment of cancer. [2004.06]
Gateways to clinical trials. [2003.11]
CD4-CD8-"Double-negative" cutaneous T-cell lymphomas share common histologic features and an aggressive clinical course. [2002.02]
Management of chronic lymphocytic leukaemia. [2000.01]
Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy. [2008]
Gateways to clinical trials. [2008.01]
Clinical management of T-cell malignancies: current perspectives, key issues, and emerging therapies. [2007.12]
Treatment of acute lymphoblastic leukaemia : a new era. [2007]
Novel purine nucleoside analogues for hematological malignancies. [2008.06]
Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. [2008.04]
Gateways to clinical trials. [2008.05]
Novel purine nucleoside analogues for hematological malignancies. [2008.06]
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics and outcome from the large randomised prospective trial (UKALL XII/ECOG 2993). [2009.10.14]
Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. [2009.03.23]
Novel therapies for relapsed acute lymphoblastic leukemia. [2009.07]
[Novel conventional therapies in onco-hemathology]. [2011.08.01]
New nucleoside analogs for patients with hematological malignancies. [2011.03]
Educational paper. The development of new therapies for pediatric oncology. [2011.05]
|
